| Literature DB >> 21794811 |
Luis Arboleya1, Mercedes Alperi, Sara Alonso.
Abstract
Aminobisphosphonates are drugs that have been used successfully in the treatment of osteoporosis for more than 20 years. Although main registry studies found a scarcity of relevant adverse events, in recent years and as a result of pharmacovigilance, different complications have been reported, some potentially serious. This has raised questions on the safety of these drugs, especially in high doses, like those used in oncology and long-term treatment, as needed in patients with osteoporosis. In this review, based on the analysis of relevant scientific evidence from clinical trials, case series, cohort studies and databases published to date, we summarize the clinical and epidemiological characteristics of the adverse effects of these drugs.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21794811 DOI: 10.1016/j.reuma.2010.10.005
Source DB: PubMed Journal: Reumatol Clin ISSN: 1699-258X